Insilico Medicine’s AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy Post author: Post published:April 14, 2024 Post category:uncategorized In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances. You Might Also Like Study exposes food insecurity among graduate students and postdocs February 21, 2024 VUMC researchers discover potent antibody against influenza B June 2, 2024 High dose psilocybin shows similar antidepressant effects to escitalopram August 21, 2024